Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

This study has been completed.
Information provided by (Responsible Party):
Aleksander Talgøy Holten, Sykehuset Innlandet HF
ClinicalTrials.gov Identifier:
First received: March 17, 2011
Last updated: July 7, 2014
Last verified: July 2014
The purpose of this study is to determine the prevalence of pulmonary embolism in our population of Chronic Obstructive Pulmonary Disease (COPD) patients admitted to hospital with dyspnea. The patients will undergo investigation for pulmonary embolism, according to current guidelines.

Pulmonary Embolism
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by Sykehuset Innlandet HF:

Primary Outcome Measures:
  • Prevalence of pulmonary embolism in exacerbations of COPD [ Time Frame: one year ] [ Designated as safety issue: No ]

Enrollment: 38
Study Start Date: April 2011
Study Completion Date: April 2013
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with known or suspected COPD admitted with an exacerbation of unknown aetiology

Inclusion Criteria:

  • known or suspected COPD
  • COPD-exacerbation

Exclusion Criteria:

  • other causes of dyspnea
  • unable to perform CT pulmonary angio (contrast allergy, pregnancy)
  • already included in the study (each patient included only once)
  • use of anticoagulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01318174

Sykehuset Innlandet
Lillehammer, Oppland, Norway, 2381
Sponsors and Collaborators
Sykehuset Innlandet HF
Principal Investigator: Aleksander T Holten, PhD Sykehuset Innlandet HF
  More Information

No publications provided

Responsible Party: Aleksander Talgøy Holten, MD, Sykehuset Innlandet HF
ClinicalTrials.gov Identifier: NCT01318174     History of Changes
Other Study ID Numbers: LE-KE
Study First Received: March 17, 2011
Last Updated: July 7, 2014
Health Authority: Norway: Regional Ethics Commitee

Keywords provided by Sykehuset Innlandet HF:
Pulmonary embolism
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Pulmonary Embolism
Cardiovascular Diseases
Embolism and Thrombosis
Respiratory Tract Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 30, 2015